Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425279 · ClinicalTrials.gov registry record · Phase 1
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
A Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, sponsored by BioAtla.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT03425279 is a Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma that has completed, run by BioAtla. The registered enrollment target is 245 participants, above the 66-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (271% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03425279, a Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-AXL-ADC
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- USC Norris Comprehensive Cancer Center - Los Angeles
- Tower Hematology Oncology Medical Group - Los Angeles
- Precision NextGen Oncology - Los Angeles
- UCSF Medical Center - Cancer Immunotherapy Clinic (CIC) - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Columbia University - New York
- Memorial Sloan Kettering - New York
Colorado
- University of Colorado - Aurora
- Sarah Cannon Research Institute at Health One - Denver
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- The University of Arizona Cancer Center - Tucson
District of Columbia
- Children's Research Institute - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425279
The ClinicalTrials.gov registry entry for NCT03425279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 66-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (271% higher). The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Undifferentiated Pleomorphic Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT03425279 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT03425279 about?
NCT03425279 is a clinical study titled "CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma". The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
What is the current status of trial NCT03425279?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2018-02-15. Estimated completion is 2025-01-08.
What conditions does trial NCT03425279 study?
This clinical trial studies the following conditions: Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma.
What interventions are being tested in trial NCT03425279?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-AXL-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03425279?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03425279 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Undifferentiated Pleomorphic Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
RECRUITING · NA
-
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
RECRUITING · Phase 2
-
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
ACTIVE NOT RECRUITING · Phase 2
-
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.